CoNCERT Pharmaceuticals Inc.

Lexington, MA

CoNCERT is creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. It applies its innovative platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities. CoNCERT leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease. Concert currently has technology licensing deals with Celgene, Jazz Pharmaceuticals and Avanir Pharmaceuticals. The company owns a number of additional preclinical and clinical assets which it has not yet licensed. The most advanced candidate is currently be evaluated in a Phase II trial to treat chronic kidney disease.

Co-investors include Adage Capital Management L.P., SR One Ltd., Westfield Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund, LP, Flagship Ventures, Greylock Partners, New Leaf Venture Partners, and QVT Fund LP. Paul Howard is a Board observer.


DiscoveRx, Inc.

Fremont, CA

DiscoveRx develops a portfolio of high performance cell and biochemical reagents for use in a broad range of drug discovery and toxicology assays. These assays include drug lead identification in high throughput screening as well as drug target identification and validation in proteomic ,genomic and primary human cell studies.

Co-investors in the company include Skyline Ventures, Morgan Stanley Ventures and Alta Partners. Paul Howard is a Board observer.


Relypsa, Inc.

Santa Clara, CA


Relypsa, Inc. is a biopharmaceutical company focused on the discovery and development of new non-absorbed polymeric drugs which exert their therapeutic effects within the gastro-intestinal tract. Relypsa’s lead product is a potassium binder that is being developed to manage hyperkalemia, a potential life-threatening side effect which can develop from drugs used to manage chronic kidney disease (CKD) and congestive heart failure (CHF). The company recently completed the enrollment of two Phase III trials under an FDA approved SPA (special protocol assessment) and expects to file an NDA by the first quarter of 2014.

Co-investors include, 5AM Ventures, New Leaf Delphi and Orbimed. Paul Howard is a Board observer.


Supplemental Health Care

Park City, UT


Supplemental provides staffing services to hospitals and other health care facilities, including traveling and local staffing of nurses, physicians and ancillary hospital personnel, such as radiology technicians, physical therapists, and occupational therapists. Supplemental is one of the top ten nurse and therapist staffing companies in the U.S.

Co-investors include GE Capital and Dauphin Capital Partners. Paul Howard is a member of the Board.


Tetraphase Pharmaceuticals, Inc.

Watertown, MA


Tetraphase Pharmaceuticals was founded by Mediphase. The company develops antibiotics in the tetracycline class, based on synthetic technology developed by Prof. Andrew Myers and licensed from Harvard University. The company which recently went public (TTPH: NASDAQ) expects to begin Phase III trials in the 2H 2013 and report data in 1Q 2015.

Co-investors include Fidelity Biosciences, Skyline Ventures, Flagship Ventures, Excel Ventures and CMEA Ventures.



Portland, OR


Wellpartner develops both traditional pharmacy benefits management products as well as 340B products and services for hospitals and commercial healthcare insurers. An important differentiator in the company’s product offering is its 340B program which is a combination of services and software to provide low cost drugs to patients in need. The government established the 340B program in the 1990s in conjunction with drug manufacturers in order to provide drugs to the poorest patients. In the past, this program has been underutilized due to the complexity of regulatory rules required to administer the plan. Wellpartner’s product simplifies and automates this process.

Co-investors include 3i Technology Partners, Integra Ventures, and Buerk Dale Victor. Paul Howard is a Board observer.